UCL Division of Medicine



The Division undertakes world-leading basic and translational research that impacts upon understanding, diagnosis and treatment of human disease.

Landmark achievements of the Division include Professor Brian Prichard’s seminal discovery that the beta-blocker, propanolol, reduces blood pressure, the development by Prof Jonathan Edwards of B cell depletion therapy (rituximab) to treat rheumatoid arthritis, and the pioneering work of the National Amyloidosis Centre established by Professor Sir Mark Pepys FRS, in non-invasive patient diagnosis and monitoring.

The Division’s research has also had economic impact through the generation of spin-off enterprises attracting major investment, such as Ark Therapeutics Ltd, co-founded by Professor John Martin, and Pentraxin Therapeutics Ltd, co-founded by Professor Sir Mark Pepys FRS. Find out more about our research by going to individual Centre or Institute websites.